
Randomized controlled trials (RCTs) are the gold standard for assessing medical treatments, but they face challenges in rare diseases like idiopathic pulmonary fibrosis (IPF). Currently, pirfenidone and nintedanib are the only approved drugs for IPF. A study assessed an innovative method using synthetic control arms to replicate RCTs, incorporating real-world data. Results indicate that synthetic controls from historical RCTs align well with placebo arms, but those from real-world data don't. This approach could enhance future IPF trials and transform treatment evaluation in pulmonary fibrosis.
Like
Save
Share